



Management of Cutaneous Squamous Cell Carcinoma Patients

Guest Editor:

Dr. Chrysalynne D. Schmults

Brigham and Women's
Department of Dermatology,
Harvard Medical School, Boston,
MA, USA

Deadline for manuscript
submissions:

closed (15 January 2022)

Message from the Guest Editor

Dear Colleagues,

The field of squamous cell carcinoma management encompasses a spectrum of diseases ranging from precursor lesions and field cancerization, where prophylaxis can improve outcomes, to small tumors that are easily removed, to aggressive diseases requiring treatment beyond surgery.

This Special Issue aims to explore all areas of treatment including:

1. prophylaxis: definitions, spectrum, and management of field cancerization;
2. diagnostic work-up, impact of tumors and nodal staging on prognosis and management;
3. surgical management including NCCN guidelines for high risk and very high risk tumors;
4. the role of adjuvant and neoadjuvant therapy, including emerging intratumoral therapy;
5. surveillance exams and imaging for timely identification of recurrence;
6. current immunotherapy systemic treatment options for diseases not amenable to cure with surgery and/or radiation;
7. systemic options for organ transplant recipients.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as incoming Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase,** and **other databases.**

Journal Rank: JCR - Q2 (*Oncology*)

Contact Us

Current Oncology Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/currenncol
currentoncology@mdpi.com
[X@CurrentOncology](https://twitter.com/CurrentOncology)